JPH0813745B2 - 有機化合物におけるまたは関する改良 - Google Patents

有機化合物におけるまたは関する改良

Info

Publication number
JPH0813745B2
JPH0813745B2 JP3514198A JP51419891A JPH0813745B2 JP H0813745 B2 JPH0813745 B2 JP H0813745B2 JP 3514198 A JP3514198 A JP 3514198A JP 51419891 A JP51419891 A JP 51419891A JP H0813745 B2 JPH0813745 B2 JP H0813745B2
Authority
JP
Japan
Prior art keywords
clozapine
free radical
ascorbic acid
radical scavenger
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP3514198A
Other languages
English (en)
Japanese (ja)
Other versions
JPH05503296A (ja
Inventor
フィッシャー、フォルカー
メイソン、ロナルド・ポール
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sandoz AG
United States Department of Commerce
Original Assignee
Sandoz AG
United States Department of Commerce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz AG, United States Department of Commerce filed Critical Sandoz AG
Publication of JPH05503296A publication Critical patent/JPH05503296A/ja
Publication of JPH0813745B2 publication Critical patent/JPH0813745B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP3514198A 1990-08-20 1991-08-14 有機化合物におけるまたは関する改良 Expired - Lifetime JPH0813745B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US56968990A 1990-08-20 1990-08-20
US71713691A 1991-06-18 1991-06-18
US717,136 1991-06-18
US569,689 1991-06-18
PCT/EP1991/001542 WO1992003138A1 (en) 1990-08-20 1991-08-14 Improvements in or relating to organic compounds

Publications (2)

Publication Number Publication Date
JPH05503296A JPH05503296A (ja) 1993-06-03
JPH0813745B2 true JPH0813745B2 (ja) 1996-02-14

Family

ID=27075116

Family Applications (1)

Application Number Title Priority Date Filing Date
JP3514198A Expired - Lifetime JPH0813745B2 (ja) 1990-08-20 1991-08-14 有機化合物におけるまたは関する改良

Country Status (30)

Country Link
US (2) US5312819A (enExample)
JP (1) JPH0813745B2 (enExample)
KR (1) KR100189349B1 (enExample)
AT (1) AT400522B (enExample)
AU (1) AU649269B2 (enExample)
BE (1) BE1006878A5 (enExample)
CA (1) CA2065421A1 (enExample)
CH (1) CH684162A5 (enExample)
CZ (1) CZ281843B6 (enExample)
DE (1) DE4191979T (enExample)
DK (1) DK51292D0 (enExample)
ES (1) ES2078838B1 (enExample)
FI (1) FI913888A7 (enExample)
FR (1) FR2665835B1 (enExample)
GB (1) GB2254252B (enExample)
GR (1) GR1002188B (enExample)
HU (1) HUT60137A (enExample)
IE (1) IE66121B1 (enExample)
IL (1) IL99224A (enExample)
IT (1) IT1251226B (enExample)
LU (1) LU88099A1 (enExample)
MX (1) MX9100742A (enExample)
MY (1) MY107976A (enExample)
NL (1) NL9120006A (enExample)
NZ (1) NZ239464A (enExample)
PT (1) PT98707B (enExample)
RU (1) RU2080860C1 (enExample)
SE (1) SE9201189D0 (enExample)
SK (1) SK279225B6 (enExample)
WO (1) WO1992003138A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993008801A1 (en) * 1991-10-31 1993-05-13 The Government Of The United States Of America As Represented By The Department Of Health And Human Services Prevention of drug-induced agranulocytosis with free radical scavengers
US5538965A (en) * 1993-12-23 1996-07-23 Allelix Biopharmaceuticals Inc. Dopamine receptor ligands
CA2167104A1 (en) * 1995-01-17 1996-07-18 Joerg G.D. Birkmayer Nadh and nadph therapeutic agents for nasal, sublingual, rectal and dermal administration
JP3889481B2 (ja) * 1996-08-16 2007-03-07 株式会社カネカ 医薬組成物
JP2001520978A (ja) * 1997-10-27 2001-11-06 コーテックス ファーマシューティカルズ， インコーポレイテッド アンパカインおよび神経遮断薬を用いる精神分裂病の処置
US8753675B1 (en) * 2000-01-20 2014-06-17 Raj K. Chopra Reduced form of Coenzyme Q in high bioavailability stable dosage forms and related applications
JP2003026567A (ja) * 2001-05-10 2003-01-29 Kanegafuchi Chem Ind Co Ltd 補酵素ｑを有効成分とする粘膜投与用組成物
NZ527142A (en) * 2003-07-23 2006-03-31 Douglas Pharmaceuticals Ltd A stable suspension formulation
EP2299983A4 (en) * 2008-07-24 2012-10-10 Handa Pharmaceuticals Llc ATYPICAL ANTIPSYCHOTIC FORMULATION STABILIZED
RU2441651C1 (ru) * 2010-12-23 2012-02-10 Маргарита Алексеевна Морозова Способ получения фармацевтической композиции клозапина в виде таблеток и фармацевтическая композиция
RU2610169C2 (ru) 2014-09-11 2017-02-08 Общество С Ограниченной Ответственностью "Валентек" ПРОИЗВОДНЫЕ 7-ФТОРО-8-ХЛОРО-5Н-ДИБЕНЗО[b, е][1, 4]ДИАЗЕПИНА И ИХ ПРИМЕНЕНИЕ

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI50242C (fi) * 1969-07-18 1976-01-12 Thomae Gmbh Dr K Menetelmä valmistaa farmakologisesti aktiivisia uusia diallyyliaminoal kanoyylidibenso- tai pyridobenso-diatsepiineja ja niiden happoadditios uoloja.
US3983234A (en) * 1974-07-04 1976-09-28 Sandoz Ltd. Treatment of dyskinesias
US4028467A (en) * 1975-01-07 1977-06-07 Berger Frank M Analgesic compositions comprising levo-propoxyphene and benzo diazepine and process
GB1498857A (en) * 1975-07-03 1978-01-25 Leo Ab Antidepressant composition
DE3069716D1 (en) * 1979-10-01 1985-01-10 Sandoz Ag Dibenzazepine derivatives, their production and pharmaceutical compositions containing them
US4761411A (en) * 1983-05-18 1988-08-02 Hoechst-Roussel Pharmaceuticals Inc. Dihydrobenzopyrrolobenzodiazepines useful for treating pyschoses
DE3542309A1 (de) * 1985-11-29 1987-06-04 Cardona Federico Dr Medizinisches antioxidativum
US4973586A (en) * 1986-01-16 1990-11-27 Schering Corporation Fused benzazepines, compositions of, and medical use thereof
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
CA1327008C (en) * 1988-01-15 1994-02-15 Walter Merz Anti-psychotic imidazobenzodiazepine
US4996199A (en) * 1988-04-08 1991-02-26 Whitby Research, Inc. Penetration enhancers for transdermal delivery of systemic agents
JP2903318B2 (ja) * 1989-04-04 1999-06-07 日研フード株式会社 抗酸化的ストレス物

Also Published As

Publication number Publication date
NL9120006A (nl) 1992-08-03
NZ239464A (en) 1993-10-26
KR100189349B1 (en) 1999-06-01
US5312819A (en) 1994-05-17
FR2665835B1 (fr) 1995-06-23
IE66121B1 (en) 1995-12-13
ITMI912261A0 (it) 1991-08-20
IL99224A (en) 1996-01-31
GB9206101D0 (en) 1992-06-24
CA2065421A1 (en) 1992-02-21
JPH05503296A (ja) 1993-06-03
SE9201189L (sv) 1992-04-14
MX9100742A (es) 1992-04-01
FI913888L (fi) 1992-02-21
ITMI912261A1 (it) 1993-02-20
MY107976A (en) 1996-07-15
HU9201090D0 (en) 1992-06-29
DK51292A (da) 1992-04-15
RU2080860C1 (ru) 1997-06-10
IL99224A0 (en) 1992-07-15
SE9201189D0 (sv) 1992-04-14
WO1992003138A1 (en) 1992-03-05
SK279225B6 (sk) 1998-08-05
FI913888A7 (fi) 1992-02-21
ES2078838B1 (es) 1997-02-01
GB2254252B (en) 1994-06-01
GR1002188B (en) 1996-03-13
DE4191979T (enExample) 1992-10-08
KR920702225A (ko) 1992-09-03
ATA900491A (de) 1995-06-15
DK51292D0 (da) 1992-04-15
HUT60137A (en) 1992-08-28
AT400522B (de) 1996-01-25
US5563134A (en) 1996-10-08
AU649269B2 (en) 1994-05-19
FR2665835A1 (fr) 1992-02-21
LU88099A1 (de) 1992-11-16
GB2254252A (en) 1992-10-07
PT98707B (pt) 1999-01-29
FI913888A0 (fi) 1991-08-16
IE912934A1 (en) 1992-02-26
GR910100361A (el) 1992-08-31
IT1251226B (it) 1995-05-05
CZ281843B6 (cs) 1997-02-12
AU8396391A (en) 1992-03-17
CH684162A5 (de) 1994-07-29
CS55092A3 (en) 1992-08-12
ES2078838A1 (es) 1995-12-16
BE1006878A5 (fr) 1995-01-17
PT98707A (pt) 1992-07-31

Similar Documents

Publication Publication Date Title
AU593051B2 (en) Method of treating alzheimer's disease
Chouinard et al. Tryptophan‐nicotinamide, imipramine and their combination in depression: a controlled study
Donlon et al. Haloperidol for acute schizophrenic patients: An evaluation of three oral regimens
RO120567B1 (ro) Compoziţie de substanţe biochimice, pentru scăderea lipoproteinei (a) din plasmă şi a factorilor de risc pentru afecţiuni cardiovasculare
JPH0813745B2 (ja) 有機化合物におけるまたは関する改良
WO2018053275A1 (en) Use of pridopidine for the treatment of familial dysautonomia
US6897212B2 (en) Treatment of oppositional defiant disorder and conduct disorder with 5-aminoalkyl-4,5,6,7-tetrahydro-4-oxyindolones
Maxwell et al. Tricyclic and monoamine oxidase inhibitor antidepressants: Structure-activity relationships
EP1964566A1 (en) Preparation with improved bioabsorbability of sapropterin hydrochloride
AU603421B2 (en) Agent having renal function-improving effect and diuretic effect
US6274621B1 (en) Ginkgolides for inhibition of membrane expression of benzodiazepine receptors
AU2004290925B2 (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
Swick et al. Peritoneal dialysis in colistin intoxication: Report of a case
US5013735A (en) Method of treating therapy-resistant schizophrenia with amperozide (N-ethyl-4-(4',4'-bis(p-fluorophenyl)butyl)-1-piperazine-carboxamide
WO2021048431A1 (en) Compounds for treating ataxia
KR20010080407A (ko) 리루졸과 알파-토코페롤의 배합물
JPS63107926A (ja) 血中脂質改善剤
EP0862428B1 (en) Ginkgolides for inhibition of membrane expression
Hollister Drug treatment of schizophrenia
JP2002114678A (ja) トコトリエノール含有医薬用剤
Gallant Antidepressant overdose: symptoms and treatment
HK1097762B (en) Pharmaceutical compositions for the treatment of renal dysfunction, disease or disorder, in particular in diabetic patients
JP2009126815A (ja) 高尿酸血症の予防または改善剤